Boehringer Ingelheim announced that the European Commission has granted marketing authorisation of the novel, oral direct thrombin inhibitor, Pradaxa® (dabigatran etexilate) in all 27 EU member state
read more » Discuss Add this link to...Bury Add to:
| Bookmarks